Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an announcement.
Pharmaron Beijing Co., Ltd. has announced an updated cash dividend for the year ending December 31, 2024, with a declared dividend of RMB 2 per 10 shares. The payment, approved on June 20, 2025, will be made in HKD at an exchange rate of RMB 1 to HKD 1.093857, with a payment date set for August 6, 2025. The announcement includes details on withholding tax rates for various shareholders, impacting non-resident enterprises and investors through stock connect programs. This dividend update reflects the company’s financial strategies and obligations to its shareholders, potentially influencing its market positioning and investor relations.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, providing a range of services including drug research and development, manufacturing, and laboratory services. The company focuses on supporting pharmaceutical and biotech companies in their drug discovery and development processes.
Average Trading Volume: 9,275,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.55B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.